Lazertinib

INDICATIONS AND USAGE

LuciLazer is a kinase inhibitor indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.

DOSAGE AND ADMINISTRATION

• The recommended dosage of LuciLazer is 240 mg orally once daily with or without food, given in combination with amivantamab.
• Continue treatment until disease progression or unacceptable toxicity.
• Administer LuciLazer any time prior to amivantamab when given on the same day.
• Refer to the amivantamab prescribing information for recommended amivantamab dosing information.
• Administer anticoagulant prophylaxis to prevent venous thromboembolic events (VTE) for the first four months of treatment.

DOSAGE FORMS AND STRENGTHS

Tablets: 80 mgx60 tablets